New Quantitative Testing System for Coronavirus Detection Could Also Diagnose Other Viral Illnesses

The COVID-19 pandemic highlighted the critical role of disease testing. Over the past few years, most people have undergone PCR (Polymerase Chain Reaction) or ELISA (Enzyme-Linked Immunosorbent Assay) tests. However, these methods have limitations, requiring large sample volumes, complex procedures, and even presenting risks of exposing testers to the virus. Now, a team of researchers has developed a new quantitative testing system that offers a simpler, faster, and more cost-effective way to detect the coronavirus N protein. This advanced microfluidic technology-based system is not limited to coronavirus detection and is expected to be applicable to other viral illnesses such as influenza and hepatitis in the future.

This novel immunoassay system called the "Express Biochecker" was developed by scientists at Tohoku University (Sendai, Japan) and is based on Janus particles. These particles, named after the two-faced Roman god Janus, feature two distinct sides: one coated with a fluorescent dye and the other with magnetic particles and antibodies. These particles are designed to specifically bind to target antigens, such as viral proteins, and are used with antibody-immobilized microfluidic devices for precise measurement.

The versatility of this system is a major advantage. It not only enables the detection of viruses in various diseases but also has the potential to be adapted for measuring other biomarkers linked to different health conditions. This adaptability could lead to new opportunities in medical diagnostics. Future research will aim to extend the system's capabilities to detect additional disease markers. The findings were detailed in the journal Langmuir.

Related Links:
Tohoku University